Aruna Biomedical Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2019 | $13 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jul 2018 | $5 M | No. 2 | $2 to $10 million | equity | SEC | |
| Aug 2016 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Aruna Biomedical Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Aug 2019).
SEC Form D (revenue range) · Aug 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2019
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Aruna Biomedical Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 81 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Al Medwar | Executive officer | Aug 2019 |
| Mark Sirgo | Executive officer | Aug 2019 |
| Steven Stice | Executive officer | Aug 2019 |
| Tracey Stice | Executive officer | Aug 2019 |
| Harold W. Ingalls | Chief Financial Officer and Director | Apr 2017 |
| Steven W. Stice | Chief Scientific Officer and Director | Apr 2017 |
| Tracey W. Stice | Chief Operating Officer and Secretary | Apr 2017 |
| Barry Storey | Director | Aug 2019 |
| C. William Griffin | Director | Aug 2019 |
| Darren DeVore | Director | Aug 2019 |
| Harold Ingalls | Director | Aug 2019 |
| John Mangan | Director | Aug 2019 |
| Mark Sirgo | Director | Aug 2019 |
| Mason Irving | Director | Aug 2019 |
| Russell Lindner | Director | Aug 2019 |
| Steven Stice | Director | Aug 2019 |
| Barry William Storey | Director | Jul 2018 |
| Darren William DeVore | Director | Jul 2018 |
| Harold William Ingalls | Director | Jul 2018 |
| John William Mangan, Jr. | Director | Jul 2018 |
| Mason William Irving, III | Director | Jul 2018 |
| Russell William Lindner | Director | Jul 2018 |
| Barry W. Storey | Director | Apr 2017 |
| Darren F. Devore | Director | Apr 2017 |
| Harold W. Ingalls | Chief Financial Officer and Director | Apr 2017 |
| John F. Mangan, Jr. | Director | Apr 2017 |
| Russell C. Lindner | Director | Apr 2017 |
| Steven W. Stice | Chief Scientific Officer and Director | Apr 2017 |
| Darren W. DeVore | Director | Aug 2016 |
| John W. Mangan, Jr. | Director | Aug 2016 |